As the tools for generating and characterising antibodies become more sophisticated and widely available, patent offices are re-evaluating how they assess key legal requirements...
As research and development efforts move forward in relation to Chimeric antigen receptor CAR-T cells, it is interesting to understand the main patentability issues of...
Genome editing using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated 9 (Cas-9) technology holds great potential to accelerate life science research, improve biotechnology, and...
Chimeric antigen receptor (CAR) T-cell therapy is a personalised cancer treatment that is gaining greater visibility and enthusiasm as research advances and success in...
Patent Term Extension (PTE) in Korea provides an opportunity to extend the term of a patent based on regulatory approval or Marketing Authorisation (MA)...
Examining a recent court decision; the latest in a long running, multi-jurisdictional dispute between the parties concerning the validity and infringement of claims to...
FICPI is the only international NGO whose membership consists exclusively of IP attorneys in private practice. As a result, the FICPI community is driven by a shared interest to promote solutions and advocacy for private IP practitioners.